Tech Company Financing Transactions
Ajax Therapeutics Funding Round
On 5/13/2024, Ajax Therapeutics raised $95 million in Series C financing from Goldman Sachs, Boxer Capital and EcoR1 Capital Management.
Transaction Overview
Company Name
Announced On
5/13/2024
Transaction Type
Venture Equity
Amount
$95,000,000
Round
Series C
Investors
Goldman Sachs (Lead Investor) (Ming Cheah)
EcoR1 Capital Management (Scott Platshon)
Proceeds Purpose
The company intends to use the funds for the clinical development of its first-in-class Type II JAK2 inhibitor, AJ1-11095, for the treatment of myelofibrosis, as well as advancing its pipeline of treatments for MPNs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
275 Madison Ave. 39th floor
New York, NY 10016
USA
New York, NY 10016
USA
Phone
Website
Email Address
Overview
Advances in molecular genetics and biology have led to the development of new classes of targeted therapies for the treatment of hematologic malignancies. However, many of these therapies, while selective for a particular drug target, often interact with other related proteins which can limit their efficacy and lead to unwanted side effects.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Martin Vogelbaum
VP - R & D
Craig Masse
Browse more venture capital transactions:
Prev: 5/13/2024: ByHeart venture capital transaction
Next: 5/13/2024: Tiney venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs